FDA warns about opioid-containing supplementFDA said the manufacturer of dietary supplements containing kratom, a natural opioid used to treat opioid use disorder, agreed to destroy the supplements, and is again warning the public about kratom.
New warning on antibiotic for heart disease patientsFDA is advising caution before healthcare professionals prescribe a certain antibiotic to patients with heart disease due to a potential increased risk of heart problems or death that can occur years later.
DEA tightens fentanyl schedulingDue to the increased use of illicit fentanyl mixed with heroin and used in counterfeit prescription drugs, the DEA placed all illicit fentanyl analogues not already regulated by the Controlled Substances Act into Schedule I.
Opioid prescription limits gain supportA pharmacist organization is among the supporters of a new Medicare Part D proposal, which calls for a 7-day supply limit on opioid prescriptions.
Cannabis-derived epilepsy drug on the horizonA pharmaceutical formulation of purified cannabidiol, a cannabinoid without euphoric side effects, is expected to launch in the second half of this year.
FDA takes tough stance on kids’ opioid cold medsFDA is taking its toughest stance yet on opioid-containing cough and cold medications for children.
Top 3 new drug approvalsHere are 3 of the top new drug approvals in late December and early January.
Top 5 pipeline drugs for 2018
Top 5 pipeline drugs for 2018New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
New treatment for advanced kidney cancer approved
New treatment for advanced kidney cancer approvedFDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
FDA approves first once-monthly injection for opioid abuseSoon after FDA approved a novel device to treat opioid use disorder, FDA approved the first and only once-monthly injectable buprenorphine formulation to treat moderate to severe opioid use disorder (OUD).


View Results